Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

被引：159

作者：

Reck, Martin ^{[1
]}

Schenker, Michael ^{[2
]}

Lee, Ki Hyeong ^{[3
]}

Provencio, Mariano ^{[4
]}

Nishio, Makoto ^{[5
]}

Lesniewski-Kmak, Krzysztof ^{[6
]}

Sangha, Randeep ^{[7
]}

Ahmed, Samreen ^{[8
]}

Raimbourg, Judith ^{[9
]}

Feeney, Kynan ^{[10
,11
]}

Corre, Romain ^{[12
]}

Franke, Fabio Andre ^{[13
]}

Richardet, Eduardo ^{[14
]}

Penrod, John R. ^{[15
]}

Yuan, Yong ^{[15
]}

Nathan, Faith E. ^{[15
]}

Bhagavatheeswaran, Prabhu ^{[15
]}

DeRosa, Michael ^{[16
]}

Taylor, Fiona ^{[16
]}

Lawrance, Rachael ^{[17
]}

Brahmer, Julie ^{[18
]}

机构：

[1] German Ctr Lung Res DZL, ARCN, LungenClin Grosshansdorf, Wohrendamm 80, D-22927 Grosshansdorf, Germany

[2] Cent Oncol Sf Nectarie, 23A Caracal St, Craiova 200347, Romania

[3] Chungbuk Natl Univ Hosp, 776,1 Sunhwan Ro, Cheongju 28644, Chungcheonbuk D, South Korea

[4] Univ Autonoma Madrid, Inst Invest Puerta Hierro, Hosp Puerta Hierro de Majadahonda, C Manuel de Falla 1, Madrid 28222, Majadahonda, Spain

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan

[6] Gdansk Med Univ, Oddzial Onkol Radioterapii Szpital, UI Powstania Styczniowego 1, PL-81519 Gdynia, Poland

[7] Cross Canc Inst, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada

[8] Univ Hosp Leicester NHS Trust, Dept Infect, Leicester LE1 5WW, Leics, England

[9] Inst Cancerol Ouest, Ctr Rene Gauducheau, Blvd Jacques Monad, F-44805 Nantes, France

[10] Notre Dame Univ, 100 Murdoch Dr, Perth, WA 6150, Australia

[11] Edith Cowan Univ, 100 Murdoch Dr, Perth, WA 6150, Australia

[12] CHU Rennes, 2 Rue Henri le Guilloux, F-35033 Rennes, France

[13] Hosp Caridade Ijui, CACON, Av David Jose Martins, BR-98700000 Ijui, RS, Brazil

[14] IONC Univ Catolica Cordoba, Parana 560 2 Piso, RA-5000 Cordoba, Argentina

[15] Bristol Myers Squibb Co, 3401 Princeton Pike, Lawrenceville, NJ 08648 USA

[16] Adelphi Values, 290 Congress St 7th Floor, Boston, MA 02210 USA

[17] Adelphi Values, Grimshaw Ln, Bollington SK10 5JB, Cheshire, England

[18] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1-G94, Baltimore, MD 21287 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷

关键词：

Antineoplastic agents; Carcinoma; Ipilimumab; Lung neoplasms; Nivolumab; Non-small-cell lung cancer; Platinum-doublet chemotherapy; Quality of life; Surveys and questionnaires; QUALITY-OF-LIFE; DOCETAXEL; SYMPTOMS; MULTICENTER;

D O I：

10.1016/j.ejca.2019.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the phase I I I CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; >= 10 mutations/megabase). Aim: To evaluate patient-reported outcomes (PROs) in this population. Methods: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. Results: In the high TMB population, PRO questionnaire completion rates were similar to 90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. Conclusion: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. (C) 2019 The Authors. Published by Elsevier Ltd.

引用

页码：137 / 147

页数：11

共 50 条

[21] First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes
Reck, Martin
Ciuleanu, Tudor-Eliade
Cobo, Manuel
Schenker, Michael
Zurawski, Bogdan
Menezes, Juliana
Richardet, Eduardo
Bennouna, Jaafar
Felip, Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurelia
Cheng, Ying
Sakai, Hiroshi
Paz-Ares, Luis
Lu, Shun
John, Thomas
Sun, Xiaowu
Moisei, Aniela
Taylor, Fiona
Lawrance, Rachael
Zhang, Xiaoqing
Sylvester, Judi
Yuan, Yong
Blum, Steven I.
Penrod, John R.
Carbone, David P.
EUROPEAN JOURNAL OF CANCER, 2023, 183 : 174 - 187
[22] Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
Li, Ziming
Lu, Shun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1172 - +
[23] First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Marth, Christian
Moore, Richard G.
Bidzinski, Mariusz
Pignata, Sandro
Ayhan, Ali
Rubio, M. Jesus
Beiner, Mario
Hall, Marcia
Vulsteke, Christof
Braicu, Elena Ioana
Sonoda, Kenzo
Wu, Xiaohua
Frentzas, Sophia
Mattar, Andre
Lheureux, Stephanie
Chen, Xiaojun
Hasegawa, Kosei
Magallanes-Maciel, Manuel
Choi, Chel Hun
Shalkova, Mariia
Kaen, Diego
Wang, Peng-Hui
Berger, Regina
Okpara, Chinyere E.
Mckenzie, Jodi
Yao, Lili
Orlowski, Robert
Khemka, Vivek
Gilbert, Lucy
Makker, Vicky
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
[24] Nivolumab (Nivo) plus Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227.
Reck, Martin
Hellmann, Matthew David
Paz-Ares, Luis G.
Ramalingam, Suresh S.
Brahmer, Julie R.
O'Byrne, Kenneth John
Bhagavatheeswaran, Prabhu
Nathan, Faith Ellen
Borghaei, Hossein
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] Nivolumab (NIVO) plus ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
Thomas, M.
Ramalingam, S. S.
Ciuleanu, T. E.
Pluzanski, A.
Lee, J. -S.
Schenker, M.
Bernabe Caro, R.
Lee, K. H.
Zurawski, B.
Audigier-Valette, C.
Provencio, M.
Linardou, H.
Kim, S. -W.
Borghaei, H.
Hellmann, M. D.
O'Byrne, K. J.
Paz-Ares, L. G.
Reck, M.
Nathan, F. E.
Brahmer, J. R.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 140 - 141
[26] Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Vogel, Arndt
Qin, Shukui
Kudo, Masatoshi
Su, Yun
Hudgens, Stacie
Yamashita, Tatsuya
Yoon, Jung-Hwan
Fartoux, Laetitia
Simon, Krzysztof
Lopez, Carlos
Sung, Max
Mody, Kalgi
Ohtsuka, Tatsuroh
Tamai, Toshiyuki
Bennett, Lee
Meier, Genevieve
Breder, Valery
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08): : 649 - 658
[27] Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
Garon, Edward B.
Cho, Byoung Chul
Reinmuth, Niels
Lee, Ki Hyeong
Luft, Alexander
Ahn, Myung-Ju
Robinet, Gilles
Le Moulec, Sylvestre
Natale, Ronald
Schneider, Jeffrey
Shepherd, Frances A.
Garassino, Marina Chiara
Geater, Sarayut Lucien
Szekely, Zsolt Papai
Van Ngoc, Tran
Liu, Feng
Scheuring, Urban
Patel, Nikunj
Peters, Solange
Rizvi, Naiyer A.
CLINICAL LUNG CANCER, 2021, 22 (04) : 301 - +
[28] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Scherpereel, A.
Antonia, S.
Bautista, Y.
Grossi, F.
Kowalski, D.
Zalcman, G.
Nowak, A.
Fujimoto, N.
Peters, S.
Tsao, A.
Mansfield, A.
Popat, S.
Sun, X.
Padilla, B.
Aanur, P.
Daumont, M.
Bennett, B.
McKenna, M.
Baas, P.
ANNALS OF ONCOLOGY, 2020, 31 : S1441 - S1441
[29] First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
Bischoff, H.
Scherpereel, A.
Antonia, S.
Bautista, Y.
Grossi, F.
Kowalski, D.
Zalcman, G.
Nowak, A.
Fujimoto, N.
Peters, S.
Tsao, A.
Mans-Field, A.
Popat, S.
Sun, X.
Padilla, B.
Aanur, P.
Daumont, M.
Bennett, B.
McKenna, M.
Baas, P.
PNEUMOLOGIE, 2021, 75 : S17 - S17
[30] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)
Kato, Ken
Doki, Yuichiro
Ogata, Takashi
Motoyama, Satoru
Kawakami, Hisato
Ueno, Masaki
Kojima, Takashi
Shirakawa, Yasuhiro
Okada, Morihito
Ishihara, Ryu
Kubota, Yutaro
Amaya-Chanaga, Carlos
Chen, Tian
Matsumura, Yasuhiro
Kitagawa, Yuko
ESOPHAGUS, 2023, 20 (02) : 291 - 301

← 1 2 3 4 5 →